Industry Analysts Just Made An Incredible Upgrade To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts
yahoo.com
news
2022-05-28 14:53:27

BridgeBio Pharma, Inc. (NASDAQ:BBIO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply increased their revenue numbers, with a view that BridgeBio Pharma will make substantially more sales than they'd previously expected.

After the upgrade, the ten analysts covering BridgeBio Pharma are now predicting revenues of US$92m in 2022. If met, this would reflect a major 29% improvement in sales compared to the last 12 months.
